Zinnia Wealth Advisory LLC Buys New Position in Catalyst Pharmaceuticals, Inc. $CPRX

Zinnia Wealth Advisory LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 23,468 shares of the biopharmaceutical company’s stock, valued at approximately $548,000.

Other large investors have also added to or reduced their stakes in the company. State Street Corp raised its holdings in Catalyst Pharmaceuticals by 7.8% in the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock worth $161,224,000 after purchasing an additional 502,235 shares in the last quarter. Deerfield Management Company L.P. boosted its stake in shares of Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. Fundsmith LLP increased its position in shares of Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock valued at $66,267,000 after buying an additional 654,721 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Catalyst Pharmaceuticals by 21.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,996,297 shares of the biopharmaceutical company’s stock worth $69,933,000 after buying an additional 538,128 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $31.36 on Monday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The firm has a 50-day moving average of $29.16 and a 200 day moving average of $25.65. The stock has a market cap of $3.84 billion, a P/E ratio of 18.02, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74.

Wall Street Analyst Weigh In

Several analysts have commented on CPRX shares. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a report on Thursday, May 7th. HC Wainwright lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a research report on Thursday, May 28th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).